Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AEterna Zentaris Inc (NASDAQ:AEZS)

0.0878
Delayed Data
As of Sep 02
 -0.0002 / -0.23%
Today’s Change
0.08
Today|||52-Week Range
1.54
-85.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$16.0M

Company Description

AEterna Zentaris, Inc. engages in the development of novel treatments in oncology and endocrinology, which currently investigating treatments for various unmet medical needs. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Quebec, Canada.

Contact Information

Æterna Zentaris, Inc.
1405, boulevard du Parc-Technologiqu
Québec Quebec G1P 4P5
P:(418) 652-8525
Investor Relations:
14186528525406

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

David A. DoddChairman, President & Chief Executive Officer
Dennis TurpinChief Financial Officer & Senior Vice President
Richard SachseSenior VP, Chief Scientific & Medical Officer
Philip A. TheodoreSecretary, Chief Administrative Officer & SVP
Eckhard G. GuentherVice President-Business Development